BSX
Boston Scientific Corporation
Cash flow statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 4.23B | 4.53B | 3.44B | 2.50B | 1.53B | 1.87B | 1.51B | 1.84B | 0.31B | 1.43B | 1.18B | 0.69B | 1.27B | 1.11B | 1.28B | 1.01B | 0.33B | 0.84B | 1.22B | 0.93B |
| 903M | 876M | 790M | 711M | 588M | 554M | 376M | 461M | 316M | 319M | 376M | 247M | 259M | 245M | 226M | 304M | 272M | 312M | 362M | 363M | |
| Free cash flow | 3.33B | 3.66B | 2.65B | 1.79B | 0.94B | 1.32B | 1.13B | 1.38B | −6.0M | 1.11B | 0.81B | 0.44B | 1.01B | 0.87B | 1.05B | 0.70B | 53M | 0.52B | 0.85B | 0.57B |
| Depreciation and amortization | 1.43B | 1.37B | 1.27B | 1.20B | 1.14B | 1.09B | 1.12B | 1.01B | 0.90B | 0.84B | 0.82B | 0.77B | 0.73B | 0.69B | 0.68B | 0.72B | 0.82B | 0.83B | 0.86B | 0.92B |
| Stock-based compensation | 313M | 299M | 266M | 233M | 220M | 194M | 170M | 157M | 140M | 127M | 116M | 107M | 103M | 105M | 108M | 128M | 150M | 144M | 138M | 122M |
| Buybacks | — | — | — | — | 0 | 0 | 535M | 0 | 0 | — | 0 | 0 | 125M | 500M | 600M | 492M | — | — | — | — |
| Dividends paid | — | — | 0 | 28M | 55M | 55M | 28M | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | 15.8% | 18.2% | 15.8% | 12.6% | 7.4% | 11.1% | 11.4% | 12.8% | −0.1% | 12.2% | 8.9% | 5.5% | 13.5% | 12.2% | 14.5% | 9.2% | 0.7% | 6.4% | 10.6% | 6.8% |